Popular terms

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      

This page is updated frequently with new Cytokine-related patent applications.




Date/App# patent app List of recent Cytokine-related patents
06/23/16
20160176941 
 Cd40l collectin fusion proteins patent thumbnailCd40l collectin fusion proteins
The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.

06/23/16
20160176927 
 Peptide for suppressing osteoclast differentiation and use thereof patent thumbnailPeptide for suppressing osteoclast differentiation and use thereof
The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (il)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of nf-κb and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-b ligand (rankl)-rank signaling pathway, and suppresses the expression of a rankl or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (trap), cathepsin k, or tnf receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration.

06/23/16
20160175459 
 Il-15 and il-15raplha sushi domain based modulokines patent thumbnailIl-15 and il-15raplha sushi domain based modulokines
The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the il-15rα or derivatives thereof; and uses thereof.. .

06/23/16
20160175398 
 Chimeric immunoreceptor useful in treating human cancers patent thumbnailChimeric immunoreceptor useful in treating human cancers
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of t lymphocytes, direct t cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific.

06/23/16
20160175397 
 Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 patent thumbnailCombination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
The present invention relates to the combination therapy of specific tumor-targeted il-2 variant immunocytokines with specific antibodies which bind human pd-l1.. .

06/16/16
20160169906 
 Methods for identifying autoimmune arthritis and for screening for inhibitor of activation of autoimmune arthritogenic t cells patent thumbnailMethods for identifying autoimmune arthritis and for screening for inhibitor of activation of autoimmune arthritogenic t cells
Provided are a method for identifying the presence or likelihood of autoimmune arthritis, the method comprising detecting (1) an anti-ribosomal protein l23a antibody or (2) ribosomal protein l23a-reactive cd4+ t cells in a sample derived from a subject; and a method for screening for a substance that inhibits the activation of autoimmune arthritogenic t cells, the method comprising the steps of bringing a test substance into contact with ribosomal protein l23a-reactive t cells, bringing the t cells into contact with ribosomal protein l23a or a fragment thereof, measuring the level of a proinflammatory cytokine secreted from the t cells, and analyzing the test substance-dependent change in the secretion level of the proinflammatory cytokine.. .
Kyoto University


06/09/16
20160159875 
 Targeting of cytokine antagonists patent thumbnailTargeting of cytokine antagonists
The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling.
Centre Hospitalier Regional Universitaire De Montpellier


06/09/16
20160159874 
 Targeted modified tnf family members patent thumbnailTargeted modified tnf family members
The present invention relates to a modified cytokine of the tnf superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the tnf superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells.
Centre Hospitalier Regional Universitaire De Montpellier


06/02/16
20160152730 
 Targeted modified il-1 family members patent thumbnailTargeted modified il-1 family members
The present disclosure relates to a modified interleukin-1 (il-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the il-1 family member cytokine is a mutant, more preferably it is a mutant il-1 with low affinity to the il-1 receptor, wherein said mutant il-1 is specifically delivered to target cells.
Centre Hospitalier Regional Universitaire De Montpellier


06/02/16
20160152705 
 Use of a cd6 binding partner and method based thereon patent thumbnailUse of a cd6 binding partner and method based thereon
The present disclosure relates to methods for treatment and prevention of disease conditions mediated by t-helper 17 (th17) and/or t-helper 1 (th1) t lymphocytes (t cells). In particular, the present disclosure relates to use of anti-cd6 antibody for treatment of disease conditions mediated by auto-reactive th17 and th1 t lymphocytes.
Center Of Molecular Immunology


06/02/16
20160151473 

Vaccines using high-dose cytokines


The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response..
Sunnybrook And Women's College Health Sciences Center


05/26/16
20160146831 

Antibody and cytokine biomarker profiling for determination of patient responsiveness


Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness.
The Board Of Trustees Of The Leland Stanford Junior University


05/26/16
20160146806 

Receptors for b7-h4


Isolated cell surface receptors for b7-h4 have been identified based on function. B7-h4 receptor activation by b7-h4 on the dendritic cell, t follicular helper cell and germinal center b cell membrane stimulates inhibitory signaling in those leukocytes.
Amplimmune, Inc.


05/26/16
20160143940 

Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems


Psa is delivered to the host by outer membrane vesicles (omvs), secretion structures that target bacterial molecules to host cells. Purified omvs direct the in vitro differentiation of functional tregs with potent suppressive activity in a psa dependent manner.
California Institute Of Technology


05/19/16
20160136205 

Targeting type i nkt cells to control inflammation


Embodiments are directed to methods and compositions for modulating cytokine responses in subject infected by a pathogen.. .
The Board Of Regents Of The University Of Texas System


05/19/16
20160136204 

Production and therapeutic uses of th1-like regulatory t cells


A unique cd4+cd25+ regulatory t cell population develops from naive cd4+cd25− t cells during a th1 polarized immune response (called th1-tr cells). These th1-tr cells can be generated by contacting naïve t cells with mature cd8α+ dendritic cells (dcs) that have been exposed to a th1 polarizing adjuvant and, in some cases, an antigen of interest.
The Board Of Trustees Of The Leland Stanford Junior University


05/12/16
20160131663 

Biomarker for psychiatric and neurological disorders


The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders.
Resvo Inc.


05/12/16
20160130357 

Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same


Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte


05/12/16
20160129110 

Immunoprotective primary mesenchymal stem cells and methods


Immunoprotective primary mesenchymal stems cells (ip-msc) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The ip-msc express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (scfv), fab or f(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., il-2, il-4, il-6, il-7, il-9, and il-12), an interferon (e.g., ifnα, ifnβ, or ifnω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides..
The Administrators Of The Tulane Educational Fund


05/12/16
20160129109 

Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer


The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (at-car) system which provides t cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αfitc-car-expressing t cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive fitc-labeled antibodies.
University Of Maryland, Baltimore


05/05/16
20160120970 

Compounds and methods for affecting cytokines


The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of tnf-a, lactoferrin, ifn-γ, il-i β, serum amyloid-a (saa), il-6 and/or β-defensin associated with infection or an immune response generally..
Zivo Biosciences, Inc.


04/28/16
20160116484 

Systems and methods for characterizing kidney diseases


The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine.
Renovar Incorporated


04/28/16
20160116469 

Immunologically active polypeptide


Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc


04/28/16
20160115227 

Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease


The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject.

04/28/16
20160114078 

Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate


The invention is directed to a bone void filler comprising a scaffold or matrix. The scaffold or matrix may include a porous inorganic matrix component.
Spinesmith Partners, L.p.


04/28/16
20160114008 

Methods for accelerating the healing of connective tissue injuries and disorders


The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments.
Stemnion, Inc.


04/21/16
20160108108 

Inflammatory disease diagnosis and methods of treatment using lipopolysaccharides-responsive beige-like anchor


Anti-cytokine therapy has revolutionized immunological disease treatment, but is not always effective and subject to treatment resistance as the cytokine cascade is highly redundant and multiple cytokines are involved in inflammation. Targeting a critical common regulator of inflammatory effectors is desirable.

04/21/16
20160108101 

Recombinant cancer therapeutic cytokine


Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of mda-7/tl-24 (“m4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to mda-7/il-24 receptors on adjacent, neighboring and distant cancer cells.

04/21/16
20160106887 

Medical device


The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as cfs compositions), such cfs compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ecs cells), including amnion-derived cellular cytokine solution (referred to herein as accs) obtained from culturing amnion-derived multipotent progenitor (amp) cells, dispersed in a polymeric coating material..

04/21/16
20160106832 

Treatment of cancer with naltrexone


The present invention provides novel therapeutic applications of low dose naltrexone (ldn). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of toll-like receptor 9 (tlr9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized.

04/14/16
20160101132 

Enhanced anabolic cytokine production and delivery system


Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins).

04/07/16
20160095954 

Fibrin microthreads


Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., rgd-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells.
Worcester Polytechnic Institute


04/07/16
20160095912 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


04/07/16
20160095911 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


04/07/16
20160095892 

Sour cherry topical biotherapeutic formulations, manufacture and treatment of human osteoarthritis symptoms


A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by cd3+ t lymphocytes in a vertebrate mammal.. .

03/31/16
20160091486 

Glatiramer acetate human monocytic cell line-based potency assay


The present invention relates to a method to determine the potency of a batch of glatiramer acetate comprising stimulating human monocytic cell line cells with an effective amount of interferon gamma (ifnγ), exposing said cells to said batch of glatiramer acetate, and determining the expression of the monocyte anti-inflammatory cytokine sil-1ra or the viability of said cells induced by glatiramer acetate.. .
Synthon B.v.


03/31/16
20160089426 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/31/16
20160089425 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/31/16
20160089424 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/24/16
20160083442 

Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use


In t lymphocytes, p38 mitogen activated protein kinase (mapk) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and dna damage-inducible alpha (gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in t cells.
The U.s.a, As Represented By The Secretary Department Of Health And Human Services


03/24/16
20160082092 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Gmbh


03/24/16
20160082085 

Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer


The present invention relates to a combination of a parvovirus and a cytokine, preferably ifny, for use in treating pancreatic cancer, in particular a terminal stage of this disease.. .
Ruprecht-karls-universitaet Heidelberg


03/24/16
20160081958 

Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response


Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (mso). The mso may be l-methionine s-sulfoximine (lsmso), l-methionine r-sulfoximine (lrmso), or diastereomeric mixture of lsmso and lrmso.

03/24/16
20160081913 

Composition for stimulating hair growth or preventing hair loss which includes extract neural stem cell and producing same


The present invention relates to a composition for stimulating hair growth or preventing hair loss, which contains a conditioned medium or extract of neural stem cells (nscs) isolated from the ventricular zone of the human brain, and to a preparation method thereof. The conditioned medium or extract of neural stem cells according to the present invention contains various growth factors and cytokines, and thus has an excellent effect on the stimulation of hair growth.
Korea University Research And Business Foundation


03/24/16
20160081329 

Modulating ischemic injury and preserving/storing tissue


The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
Stemnion, Inc.


03/17/16
20160077107 

Personalised medicine


The present invention relates to a method for assessing the efficacy of an inhibitor of a pro-inflammatory cytokine and/or of b cells in a subject and a method for treating said subject with said inhibitor provided the efficacy of said inhibitor has been determined as sufficient.. .
Stichting Katholieke Universiteit


03/17/16
20160077102 

Diagnostic biomarker to predict women at risk for preterm delivery


The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery.
Cedars-sinai Medical Center


03/17/16
20160075996 

Method for producing nk cell-enriched blood preparation


It is intended to provide a method for producing an nk cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing nk cells, etc. In blood collected from an organism.
Biotherapy Institute Of Japan


03/17/16
20160075739 

Peptide for inducing mast cell-specific apoptosis and use thereof


A peptide according to the present invention can perform a function identical or similar to the function of natural ctla-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (cd80 and cd86) to inhibit activity of t cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, il-2 and ifn-γ).
Caregen Co., Ltd.


03/17/16
20160074537 

Immunoconjugates for the treatment of tumours


A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (ttm) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.. .
Molmed Spa


03/17/16
20160074473 

Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties


The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β hdl, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines tnf-α, il-1β, and/or il-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


03/17/16
20160074437 

Immunological treatment of liver failure


Disclosed are means of treatment of liver failure and augmentation of liver regeneration by utilization of immune modulation through administration of immunocytes and mesenchymal stem cells. In one embodiment liver failure is treated by cord blood mononuclear cells administered allogeneic to the host that have been pretreated with hepatogenic cytokines..
Batu Biologics, Inc.


03/10/16
20160070884 

Systems and methods for detecting infectious diseases


Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.


03/10/16
20160069882 

Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis


The present invention relates to a method for identifying inhibitors of breast cancer metastasis based on a screening with proteins that are specific for the secretome of a chondrocyte, preferably cytokines and/or chemokines. The ligands as identified lead to a decrease of the migration and/or a re-differentiation of a breast cancer cell and/or a reduction of the number and/or size of breast cancer metastases.
Albert-ludwigs-universitÄt Freiburg


03/10/16
20160068584 

Cytokine derived treatment with reduced vascular leak syndrome


The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an il-15 derivative conjugate so as to induce a proliferation of natural killer cells (nk cells) which is the same or higher than the one obtained with high dose of interleukin-2 (hdil-2); eventually associated with a pharmaceutically acceptable carrier.. .
Institut Gustave Roussy (igr)


03/10/16
20160067357 

Detection of high risk drusen


In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some aspects, methods of detecting high risk drusen are provided.
Apellis Pharmaceuticals, Inc.


03/10/16
20160067356 

Genetically modified human natural killer cell lines


The invention provides a natural killer cell, nk-92, modified to express an fc receptor on the surface of the cell, such as cd 16 (fcγriii-a), or other fcγ or fc receptors. The modified nk-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as fcεri-γ,tcr-ζ, or to concurrently express interleukin-2 (il-2) or other cytokines.
Fox Chase Cancer Center


03/10/16
20160067284 

Method for producing sheet-shaped cell culture


A sheet-shaped cell culture and method for producing a sheet-shaped cell culture are disclosed having a high activity such as high cytokine productivity and a production method thereof. The method for producing a sheet-shaped cell culture can include freezing cells, thawing the frozen cells and forming a sheet-shaped cell culture.
Terumo Kabushiki Kaisha


03/10/16
20160067270 

Use of ginsenoside f2 for prophylaxis and treatment of liver disease


Provided are use of ginsenoside f2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside f2. Ginsenoside f2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory t cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine il-10 in regulatory t cells, and inhibits differentiation of naive t cells into th17 cells, and is thereby effectively used for the treatment of various liver diseases..
Intelligent Synthetic Biology Center


03/03/16
20160060323 

Zcytor17 heterodimeric cytokine receptor


Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto..
Zymogenetics, Inc.


03/03/16
20160060314 

Development of a protein-based biotherapeutic agent that penetrates cell-membrane and induces anti-tumor effect in solid tumors - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-tumor compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060313 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-angiogenic effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-angiogenic compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060312 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-pancreatic cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-pancreatic cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060311 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-lung cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-lung cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060310 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-hepatocellular carcinoma effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-hepatocellular carcinoma compositions comprising the same


Protein transduction exploits the ability of some cell-penetrating peptide (cpp) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic cpps, named membrane translocating sequence (mts), membrane translocating motif (mtm) and macromolecule transduction domain (mtd), are able to deliver biologically active proteins into a variety of cells and tissues.
Cellivery Therapeutics, Inc.




Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5789

4651

2 - 1 - 105